About Lundbeck Research USA, Inc.

Receptor-specific drugs provide a new model in drug discovery that can improve the state-of-the-art treatment for many serious and common disorders.  Lundbeck Research USA uses this discovery model to pursue novel treatments for CNS diseases.  Our talented scientists have achieved influential discoveries in genomics (the cloning of genes) and functional genomics (the identification of a given receptor’s physiological function), making us a world leader in G Protein-Coupled Receptor (GPCR) discovery research. 

 As the Research Center of Excellence for Depression and Anxiety in the United States we support our parent company, H. Lundbeck A/S.  A global company headquartered in Denmark, Lundbeck is a world leader in the development of pharmaceuticals for psychiatric and neurological disorders. Research and development efforts have recently resulted in the successful development of Cipralex ® (escitalopram) – the first compound of the next-generation selective serotonin reuptake inhibitors (SSRIs).

 The scientific expertise at Lundbeck Research USA will ensure the continuation of a rich pipeline of drug discovery candidates for H. Lundbeck A/S.